Search

Your search keyword '"Bremont C"' showing total 21 results
Start Over Author "Bremont C"
21 results on '"Bremont C"'

3. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases

Author

Bernard, C., Maucort-Boulch, D., Varron, L., Charlier, C., Sitbon, K., Freymond, N., Bouhour, D., Hot, A., Masquelet, A.C., Valeyre, D., Costedoat-Chalumeau, N., Etienne, M., Gueit, I., Jouneau, S., Delaval, P., Mouthon, L., Pouget, J., Serratrice, J., Brion, J.-P., Vaylet, F., Bremont, C., Chennebault, J.M., Jaffuel, S., Broussolle, C., Lortholary, O., and Sève, P.

Published
2013
Full Text
View/download PDF

9. Poster Session 3: Friday 9 December 2011, 08:30-12:30 * Location: Poster Area

Author

Kenny, C., primary, Adhya, S., additional, Dworakowski, R., additional, Brickham, B., additional, Maccarthy, P., additional, Monaghan, M., additional, Guzzo, A., additional, Innocenti, F., additional, Vicidomini, S., additional, Lazzeretti, D., additional, Squarciotta, S., additional, De Villa, E., additional, Donnini, C., additional, Bulletti, F., additional, Guerrini, E., additional, Pini, R., additional, Bendjelid, K., additional, Viale, J., additional, Duperret, S., additional, Piriou, V., additional, Jacques, D., additional, Shahgaldi, K., additional, Silva, C., additional, Pedro, F., additional, Deister, L., additional, Brodin, L.-A., additional, Sahlen, A., additional, Manouras, A., additional, Winter, R., additional, Berjeb, N., additional, Cimadevilla, C., additional, Dreyfus, J., additional, Cueff, C., additional, Malanca, M., additional, Chiampan, A., additional, Vahanian, A., additional, Messika-Zeitoun, D., additional, Muraru, D., additional, Peluso, D., additional, Dal Bianco, L., additional, Beraldo, M., additional, Solda', E., additional, Tuveri, M., additional, Cucchini, U., additional, Al Mamary, A., additional, Badano, L., additional, Iliceto, S., additional, Almuntaser, I., additional, King, G., additional, Norris, S., additional, Daly, C., additional, Ellis, E., additional, Murphy, R., additional, Erdei, T., additional, Denes, M., additional, Kardos, A., additional, Foldesi, C., additional, Temesvari, A., additional, Lengyel, M., additional, Bouzas Mosquera, A., additional, Broullon, F., additional, Alvarez-Garcia, N., additional, Peteiro, J., additional, Barge-Caballero, G., additional, Lopez-Perez, M., additional, Lopez-Sainz, A., additional, Castro-Beiras, A., additional, Luotolahti, M., additional, Luotolahti, H., additional, Kantola, I., additional, Viikari, J., additional, Andersen, M., additional, Ersboell, M., additional, Bro-Jeppesen, J., additional, Gustafsson, F., additional, Koeber, L., additional, Hassager, C., additional, Moller, J., additional, Coisne, D., additional, Diakov, C., additional, Vallet, F., additional, Lequeux, B., additional, Blouin, P., additional, Christiaens, L., additional, Esposito, R., additional, Santoro, A., additional, Schiano Lomoriello, V., additional, Raia, R., additional, Santoro, C., additional, De Simone, G., additional, Galderisi, M., additional, Abdula, G., additional, Kosmala, W., additional, Szczepanik-Osadnik, H., additional, Przewlocka-Kosmala, M., additional, Mysiak, A., additional, O' Moore-Sullivan, T., additional, Marwick, T., additional, Tan, Y. T., additional, Wenzelburger, F., additional, Leyva, F., additional, Sanderson, J., additional, Pichler, P., additional, Syeda, B., additional, Hoefer, P., additional, Zuckermann, A., additional, Binder, T., additional, Fijalkowski, M., additional, Koprowski, A., additional, Galaska, R., additional, Blaut, K., additional, Sworczak, K., additional, Rynkiewicz, A., additional, Lee, S., additional, Kim, W., additional, Jung, L., additional, Yun, H., additional, Song, M., additional, Ko, J., additional, Khalifa, E. A., additional, Szymanski, P., additional, Lipczynska, M., additional, Klisieiwcz, A., additional, Hoffman, P., additional, Jorge, C., additional, Silva Marques, J., additional, Robalo Martins, S., additional, Calisto, C., additional, Mieiro, M., additional, Vieira, S., additional, Correia, M., additional, Carvalho De Sousa, J., additional, Almeida, A., additional, Nunes Diogo, A., additional, Park, C., additional, March, K., additional, Tillin, T., additional, Mayet, J., additional, Chaturvedi, N., additional, Hughes, A., additional, Di Bello, V., additional, Giannini, C., additional, Delle Donne, M., additional, De Sanctis, F., additional, Spontoni, P., additional, Cucco, C., additional, Corciu, A., additional, Grigoratos, C., additional, Bogazzi, F., additional, Balbarini, A., additional, Enescu, O., additional, Suran, B., additional, Florescu, M., additional, Cinteza, M., additional, Vinereanu, D., additional, Higuchi, Y., additional, Iwakura, K., additional, Okamura, A., additional, Date, M., additional, Fujii, K., additional, Cortez-Dias, N., additional, Silva, D., additional, Carrilho-Ferreira, P., additional, Magalhaes, A., additional, Ribeiro, S., additional, Goncalves, S., additional, Fiuza, M., additional, Pinto, F., additional, Placido, R., additional, Bordalo, A., additional, Grzywocz, P., additional, Mizia-Stec, K., additional, Chudek, J., additional, Gasior, Z., additional, Maceira Gonzalez, A. M., additional, Cosin Sales, J., additional, Dalli, E., additional, Igual, B., additional, Diago, J., additional, Aguilar, J., additional, Ruvira, J., additional, Cimino, S., additional, Pedrizzetti, G., additional, Tonti, G., additional, Canali, E., additional, Petronilli, V., additional, Boccalini, F., additional, Mattatelli, A., additional, Hiramoto, Y., additional, Iacoboni, C., additional, Agati, L., additional, Trifunovic, D., additional, Ostojic, M., additional, Vujisic-Tesic, B., additional, Petrovic, M., additional, Nedeljkovic, I., additional, Banovic, M., additional, Boricic-Kostic, M., additional, Draganic, G., additional, Tesic, M., additional, Gavina, C., additional, Lopes, R., additional, Lourenco, A., additional, Almeida, J., additional, Rodrigues, J., additional, Pinho, P., additional, Zamorano, J., additional, Leite-Moreira, A., additional, Rocha-Goncalves, F., additional, Clavel, M.-A., additional, Capoulade, R., additional, Dumesnil, J., additional, Mathieu, P., additional, Despres, J.-P., additional, Pibarot, P., additional, Bull, S., additional, Pitcher, A., additional, Augustine, D., additional, D'arcy, J., additional, Karamitsos, T., additional, Rai, A., additional, Prendergast, B., additional, Becher, H., additional, Neubauer, S., additional, Myerson, S., additional, Magne, J., additional, Donal, E., additional, Davin, L., additional, O'connor, K., additional, Pirlet, C., additional, Rosca, M., additional, Szymanski, C., additional, Cosyns, B., additional, Pierard, L., additional, Lancellotti, P., additional, Calin, A., additional, Popescu, B., additional, Beladan, C., additional, Enache, R., additional, Lupascu, L., additional, Sandu, C., additional, Ginghina, C., additional, Kamperidis, V., additional, Hadjimiltiadis, S., additional, Sianos, G., additional, Anastasiadis, K., additional, Grosomanidis, V., additional, Efthimiadis, G., additional, Karvounis, H., additional, Parharidis, G., additional, Styliadis, I., additional, Gonzalez Canovas, C., additional, Munoz-Esparza, C., additional, Bonaque Gonzalez, J., additional, Fernandez, A., additional, Salar Alcaraz, M., additional, Saura Espin, D., additional, Pinar Bermudez, E., additional, Oliva-Sandoval, M., additional, De La Morena Valenzuela, G., additional, Valdes Chavarri, M., additional, Brochet, E., additional, Lepage, L., additional, Attias, D., additional, Detaint, D., additional, Himbert, D., additional, Iung, B., additional, Pirat, B., additional, Little, S., additional, Chang, S., additional, Tiller, L., additional, Kumar, R., additional, Zoghbi, W., additional, Lee, A. P.-W., additional, Hsiung, M., additional, Wan, S., additional, Wong, R., additional, Luo, F., additional, Fang, F., additional, Xie, J., additional, Underwood, M., additional, Sun, J., additional, Yu, C., additional, Jansen, R., additional, Tietge, W., additional, Sijbrandij, K., additional, Cramer, M., additional, De Heer, L., additional, Kluin, J., additional, Chamuleau, S. A. J., additional, Oliveras Vila, T., additional, Ferrer Sistach, E., additional, Delgado Ramis, L., additional, Lopez Ayerbe, J., additional, Vallejo Camazon, N., additional, Gual Capllonch, F., additional, Garcia Alonso, C., additional, Teis Soley, A., additional, Ruyra Baliarda, X., additional, Bayes Genis, A., additional, Negrea, S., additional, Alexandrescu, C., additional, Bourlon, F., additional, Civaia, F., additional, Dreyfus, G., additional, Paetzold, S., additional, Luha, O., additional, Hoedl, R., additional, Stoschitzky, G., additional, Pfeiffer, K., additional, Zweiker, D., additional, Pieske, B., additional, Maier, R., additional, Sevilla, T., additional, Revilla, A., additional, Lopez, J., additional, Vilacosta, I., additional, Arnold, R., additional, Gomez, I., additional, San Roman, J., additional, Nikcevic, G., additional, Djordjevic Dikic, A., additional, Djordjevic, S., additional, Raspopovic, S., additional, Jovanovic, V., additional, Kircanski, B., additional, Pavlovic, S., additional, Milasinovic, G., additional, Ruiz-Zamora, I., additional, Cabrera Bueno, F., additional, Molina, M., additional, Fernandez-Pastor, J., additional, Pena, J., additional, Linde, A., additional, Barrera, A., additional, Alzueta, J., additional, Bremont, C., additional, Bensaid, A., additional, Alonso, H., additional, Zaghden, O., additional, Nahum, J., additional, Dubois-Rande, J., additional, Gueret, P., additional, Lim, P., additional, Lee, S.-P., additional, Park, K., additional, Kim, H.-R., additional, Lee, J.-H., additional, Ahn, H.-S., additional, Kim, J.-H., additional, Kim, H.-K., additional, Kim, Y.-J., additional, Sohn, D.-W., additional, Niemann, M., additional, Herrmann, S., additional, Hu, K., additional, Liu, D., additional, Beer, M., additional, Ertl, G., additional, Wanner, C., additional, Takenaka, T., additional, Tei, C., additional, Weidemann, F., additional, Madeira, H., additional, Mendes Pedro, M., additional, Brito, D., additional, Ippolito, R., additional, De Palma, D., additional, Gati, S., additional, Oxborough, D., additional, Reed, M., additional, Zaidi, A., additional, Ghani, S., additional, Sheikh, N., additional, Papadakis, M., additional, Sharma, S., additional, Chow, V., additional, Ng, A., additional, Pasqualon, T., additional, Zhao, W., additional, Hanzek, D., additional, Chung, T., additional, Yeoh, T., additional, Kritharides, L., additional, Magda, L., additional, Mihalcea, D., additional, Jinga, D., additional, Mincu, R., additional, Ferrazzi, E., additional, Segato, G., additional, Folino, F., additional, Famoso, G., additional, Senzolo, M., additional, Bellu, R., additional, Corbetti, F., additional, Tona, F., additional, Azevedo, O., additional, Quelhas, I., additional, Guardado, J., additional, Fernandes, M., additional, Pereira, V., additional, Medeiros, R., additional, Sousa, P., additional, Santos, W., additional, Pereira, S., additional, Marques, N., additional, Mimoso, J., additional, Marques, V., additional, Jesus, I., additional, Rustad, L., additional, Nytroen, K., additional, Gullestad, L., additional, Amundsen, B., additional, Aakhus, S., additional, Linhartova, K., additional, Sterbakova, G., additional, Necas, J., additional, Kovalova, S., additional, Cerbak, R., additional, Nelassov, N., additional, Korotkijan, N., additional, Shishkina, A., additional, Gagieva, B., additional, Nagaplev, M., additional, Eroshenko, O., additional, Morgunov, M., additional, Parmon, S., additional, Velthuis, S., additional, Van Gent, M., additional, Post, M., additional, Westermann, C., additional, Mager, J., additional, Snijder, R., additional, Koyalakonda, S. P., additional, Anderson, M., additional, Burgess, M., additional, Bergenzaun, L., additional, Chew, M., additional, Ohlin, H., additional, Gjerdalen, G. F., additional, Hisdal, J., additional, Solberg, E., additional, Andersen, T., additional, Radunovic, Z., additional, Steine, K., additional, Rutz, T., additional, Kuehn, A., additional, Petzuch, K., additional, Pekala, M., additional, Elmenhorst, J., additional, Fratz, S., additional, Mueller, J., additional, Hager, A., additional, Hess, J., additional, Vogt, M., additional, Van Der Linde, D., additional, Van De Laar, I., additional, Wessels, M., additional, Bekkers, J., additional, Moelker, A., additional, Tanghe, H., additional, Van Kooten, F., additional, Oldenburg, R., additional, Bertoli-Avella, A., additional, Roos-Hesselink, J., additional, Cresti, A., additional, Fontani, L., additional, Calabria, P., additional, Capati, E., additional, Severi, S., additional, Lynch, M., additional, Saraf, S., additional, Sandler, B., additional, Yoon, S., additional, Kim, S., additional, Ko, C., additional, Ryu, S., additional, Byun, Y., additional, Seo, H., additional, Ciampi, Q., additional, Rigo, F., additional, Pratali, L., additional, Gherardi, S., additional, Villari, B., additional, Picano, E., additional, Sicari, R., additional, Celutkiene, J., additional, Zakarkaite, D., additional, Skorniakov, V., additional, Zvironaite, V., additional, Grabauskiene, V., additional, Sinicyna, J., additional, Gruodyte, G., additional, Janonyte, K., additional, Laucevicius, A., additional, O'driscoll, J., additional, Schmid, K., additional, Marciniak, A., additional, Saha, A., additional, Gupta, S., additional, Smith, R., additional, Sharma, R., additional, Alvarez Garcia, N., additional, Prada, O., additional, Rodriguez Vilela, A., additional, Barge Caballero, G., additional, Lopez Perez, M., additional, Lopez Sainz, A., additional, Castro Beiras, A., additional, Kochanowski, J., additional, Scislo, P., additional, Piatkowski, R., additional, Grabowski, M., additional, Marchel, M., additional, Roik, M., additional, Kosior, D., additional, Opolski, G., additional, Van De Heyning, C. M., additional, Mahjoub, H., additional, Clausen, H., additional, Basaggianis, C., additional, Newton, J., additional, Del Pasqua, A., additional, Carotti, A., additional, Di Carlo, D., additional, Cetrano, E., additional, Toscano, A., additional, Iacobelli, R., additional, Esposito, C., additional, Chinali, M., additional, Pongiglione, G., additional, Rinelli, G., additional, Larsson, M., additional, Bjallmark, A., additional, Caidahl, K., additional, Brodin, L., additional, Gao, H., additional, Lugiez, M., additional, Guivier, C., additional, Rieu, R., additional, D'hooge, J., additional, Hang, G., additional, Guerin, C., additional, Menard, M., additional, Voigt, J.-U., additional, Dungu, J., additional, Campos, G., additional, Jaffarulla, R., additional, Gomes-Pereira, S., additional, Sutaria, N., additional, Baker, C., additional, Nihoyannopoulos, P., additional, Bellamy, M., additional, Harries, D., additional, Walker, N., additional, Pearson, P., additional, Reiken, J., additional, Batteson, J., additional, Kamdar, R., additional, Murgatroyd, F., additional, D'andrea, A., additional, Riegler, L., additional, Scarafile, R., additional, Pezzullo, E., additional, Salerno, G., additional, Bossone, E., additional, Limongelli, G., additional, Russo, M., additional, Pacileo, G., additional, Calabro', R., additional, Kang, Y., additional, Cui, J., additional, Chen, H., additional, Pan, C., additional, Shu, X., additional, Kiotsekoglou, A., additional, Saha, S., additional, Toole, R., additional, Govind, S., additional, Gopal, A., additional, Crispi, F., additional, Bijnens, B., additional, Sepulveda-Swatson, E., additional, Rojas-Benavente, J., additional, Dominguez, J., additional, Illa, M., additional, Eixarch, E., additional, Sitges, M., additional, Gratacos, E., additional, Prinz, C., additional, Faludi, R., additional, Walker, A., additional, Amzulescu, M., additional, Uejima, T., additional, Fraser, A., additional, Voigt, J., additional, Esmaeilzadeh, M., additional, Maleki, M., additional, Amin, A., additional, Vakilian, F., additional, Noohi, F., additional, Ojaghi Haghighi, Z., additional, Nakhostin Davari, P., additional, Bakhshandeh Abkenar, H., additional, Rimbas, R., additional, Dulgheru, R., additional, Margulescu, A., additional, D' Asaro, M., additional, Mizzon, C., additional, Parisi, F., additional, Jung, B.-C., additional, Lee, B.-Y., additional, Kang, H.-J., additional, Kim, M., additional, Kim, Y., additional, Cho, D., additional, Park, S., additional, Hong, S., additional, Lim, D., additional, Shim, W., additional, Bellsham-Revell, H., additional, Tibby, S., additional, Bell, A. J., additional, Miller, O. I., additional, Greil, G., additional, Simpson, J. M., additional, Providencia, R. A., additional, Trigo, J., additional, Botelho, A., additional, Gomes, P., additional, Seca, L., additional, Barra, S., additional, Faustino, A., additional, Costa, G., additional, Quintal, N., additional, Leitao-Marques, A., additional, Nestaas, E., additional, Stoylen, A., additional, Fugelseth, D., additional, Mornos, C., additional, Ionac, A., additional, Petrescu, L., additional, Cozma, D., additional, Dragulescu, D., additional, Mornos, A., additional, Pescariu, S., additional, Fontana, A., additional, Abbate, M., additional, Cazzaniga, M., additional, Giannattasio, C., additional, Trocino, G., additional, Laser, K., additional, Faber, L., additional, Fischer, M., additional, Koerperich, H., additional, Kececioglu, D., additional, Elnoamany, M. F., additional, Dawood, A., additional, Elhabashy, M., additional, Khalil, Y., additional, Piriou, N., additional, Warin-Fresse, K., additional, Caza, M., additional, Fau, G., additional, Crochet, D., additional, Xhabija, N., additional, Allajbeu, I., additional, Petrela, E., additional, Heba, M., additional, Barreiro Perez, M., additional, Martin Fernandez, M., additional, Renilla Gonzalez, A., additional, Florez Munoz, J., additional, Fernandez Cimadevilla, O., additional, Alvarez Pichel, I., additional, Velasco Alonso, E., additional, Leon Duran, D., additional, Benito Martin, E., additional, Secades Gonzalez, S., additional, Gargani, L., additional, Pang, P., additional, Davis, E., additional, Schumacher, A., additional, Silva Ferreira, A., additional, Bettencourt, N., additional, Matos, P., additional, Oliveira, L., additional, Cosin-Sales, J., additional, Lopez Lereu, M., additional, Monmeneu, J., additional, Estornell, J., additional, Tsverava, M., additional, Tsverava, D., additional, Varela, A., additional, Salagianni, M., additional, Galani, I., additional, Andreakos, E., additional, Davos, C., additional, Ikonomidis, I., additional, Lekakis, J., additional, Tritakis, V., additional, Kadoglou, N., additional, Papadakis, J., additional, Trivilou, P., additional, Tzortzis, S., additional, Koukoulis, C., additional, Paraskevaidis, I., additional, Anastasiou-Nana, M., additional, Kim, G., additional, Youn, H., additional, Ibrahimi, P., additional, Bajraktari, G., additional, Jashari, F., additional, Ahmeti, A., additional, Poniku, A., additional, Haliti, E., additional, Henein, M., additional, Pezo Nikolic, B., additional, Jurin, H., additional, Lovric, D., additional, Baricevic, Z., additional, Ivanac Vranesic, I., additional, Lovric Bencic, M., additional, Ernst, A., additional, and Separovic Hanzevacki, J., additional

Published
2011
Full Text
View/download PDF

10. Oral Abstract Session: New dimensions in left ventricular assessment * Thursday 8 December 2011, 11:00-12:30 * Location: Kaposvar

Author

D'asaro, M., primary, Chinali, M., additional, Toscano, A., additional, Iacobelli, R., additional, Del Pasqua, A., additional, Esposito, C., additional, Del Mastro, A., additional, Parisi, F., additional, Pongiglione, G., additional, Rinelli, G., additional, Chang, S.-A., additional, Kim, E.-Y., additional, Ahn, G.-T., additional, Heo, J.-A., additional, Choi, J.-O., additional, Lee, S.-C., additional, Park, S.-W., additional, Jeon, E.-S., additional, Oh, J.-K., additional, Ippolito, R., additional, Esposito, R., additional, Schiano Lomoriello, V., additional, Santoro, A., additional, Raia, R., additional, Schiattarella, P., additional, Galderisi, M., additional, Trache, T., additional, Stoebe, S., additional, Tarr, A., additional, Hagendorff, A., additional, Bremont, C., additional, Macron, L., additional, Hayat, D., additional, Nahum, J., additional, Bensaid, A., additional, Gueret, P., additional, and Lim, P., additional

Published
2011
Full Text
View/download PDF

13. Moderated Posters session * The emerging role of 2-dimensional strain in clinical practice: 13/12/2013, 14:00-18:00 * Location: Moderated Poster area

Author

Muraru, D, Mihaila, S, Piasentini, E, Casablanca, S, Naso, P, Puma, L, Ermacora, D, Zoppellaro, G, Iliceto, S, Badano, LP, Farsalinos, K, Daraban, A, Unlu, S, Pellikka, P, Lancellotti, P, Thomas, J, Badano, L, Voigt, J-U, Force, EACVI-ASE Standardization Task, Antoine, C, Dadfarin-Bejou, A, Gallet, R, Bremont, C, Dubois-Rande, JL, Lim, P, Acosta Martinez, J, Lopez-Haldon, JE, Rodriguez-Rodriguez, JE, Lopez-Pardo, F, Martinez-Martinez, A, Nylander, E, Hard, L, Andersson, J, Lindqvist, P, Remmets, J, Winter, R, Andersson, B, Roijer, A, Gao, S, Maret, E, Esposito, R, Santoro, C, Raia, R, Schiano-Lomoriello, V, Lauria, R, Arpino, G, De Simone, G, Galderisi, M, El Ghannudi, S, Samet, H, Germain, P, Jeung, MI-Y, Gangi, A, Roy, C, Marta, L, Placido, R, Ramalho, A, Cortez-Dias, N, Nobre Menezes, M, Santos, L, Infante Oliveira, E, Martins, S, Almeida, AG, Nunes Diogo, A, Bech-Hanssen, O, Pergola, V, Fadel, BM, Di Salvo, G, Buccheri, S, Mangiafico, S, Lavanco, V, Bottari, VE, Arcidiacono, A, Tamburino, C, and Monte, I P

Abstract

Purpose: Intervendor differences of 2D/3D strain measurements are well known issues that significantly limit their adoption in clinical routine. Whether a similar discordance affects also the quantitation of left ventricular (LV) geometry and function and the LV normative ranges for different 3D echo softwares has not been investigated. Methods: Full-volume LV 3D data sets (35±6 vps) have been acquired in 235 healthy volunteers (44±14 years, range 18–76 years, 104 men) using a GE Vivid E9 scanner. Exclusion criteria were athletic training, pregnancy, body mass index > 30 kg/m2, and poor apical acoustic window. An experienced researcher analyzed all LV data sets using a vendor-specific software (EchoPac BT12, GE Healthcare, N). Three months later, the same researcher repeated the analysis with a vendor-independent DICOM-based software (4D LV Analysis 3.1, TomTec, D), being blinded from previous measurements. Results: Despite the differences in LV parameters obtained with the two softwares were statistically significant (Table), Bland-Altman analysis shows a clinically irrelevant bias and reasonable limits of agreement for LV volumes and EF. LV mass measurements by EchoPac were slightly larger than those by TomTec and had relatively wider limits of agreement than LV volumes. Both softwares showed significant and consistent relationships of LV 3D parameters with age, gender and body size in healthy subjects (p<0.0001 for all relationships). Conclusion: Our data shows that converting 3D data sets in DICOM format does not significantly affect the normative values for LV volumes and ejection fraction with respect to those provided by proprietary software. The availability of vendor-independent softwares and respective normative values will encourage the adoption of 3D echocardiography for routine LV quantitation in multi-vendor echo labs. Vendor-specific softwareVendor-independent softwarepBiasLimits of agreementEnd-diastolic volume (ml)108±26106±250.0022-17 to +21End-systolic volume (ml)40±1139±110.5160.2-8 to +9Stroke-volume (ml)68±1666±15<0.0012-13 to +17Ejection fraction (%)64±463±40.0071-6 to +7Mass (g)133±22124±28<0.0019-24 to +43

Published
2013
Full Text
View/download PDF

14. Left ventricular dyssynchrony and 2D and 3D global longitudinal strain for differentiating physiological and pathological left ventricular hypertrophy.

Author

Ternacle J, Bremont C, d'Humieres T, Faivre L, Doan HL, Gallet R, Oliver L, Dubois-Randé JL, and Lim P

Subjects
Adult, Aged, Area Under Curve, Biomechanical Phenomena, Cardiomyopathy, Hypertrophic physiopathology, Chi-Square Distribution, Diagnosis, Differential, Football, Humans, Hypertrophy, Left Ventricular physiopathology, Image Interpretation, Computer-Assisted, Logistic Models, Middle Aged, Observer Variation, Predictive Value of Tests, Prognosis, ROC Curve, Reproducibility of Results, Retrospective Studies, Stress, Mechanical, Ventricular Dysfunction, Left physiopathology, Young Adult, Cardiomegaly, Exercise-Induced, Cardiomyopathy, Hypertrophic diagnostic imaging, Echocardiography, Doppler, Echocardiography, Three-Dimensional, Hypertrophy, Left Ventricular diagnostic imaging, Myocardial Contraction, Ventricular Dysfunction, Left diagnostic imaging, Ventricular Function, Left
Abstract

Background: Diagnosis of hypertrophic cardiomyopathy (HCM) in athletes can be challenging., Aims: To ascertain parameters that differentiate patients with HCM from athletes with moderate left ventricular (LV) hypertrophy (LVH 13-15mm)., Methods: We retrospectively included 100 men: 50 elite rugby players (25 with moderate LVH and 25 with no LVH), 25 patients with HCM and moderate LVH and 25 controls. LV dyssynchrony was defined as the standard deviation of time to peak 2D longitudinal strain (16-segment model) and global strain components were computed from two- (2D) and three-dimensional (3D) speckle tracking., Results: 2D global longitudinal strain (GLS) (18±2% vs. 19±2%) and various 3D strain components were similar in athletes with moderate LVH and controls, while LV volumes and dyssynchrony (39±8 vs. 31±9ms; P<0.001) were greater in athletes with moderate LVH. The accuracy for differentiating patients with HCM from athletes ranged between 0.57 and 0.92 for various markers, with the best obtained for LV dyssynchrony (AUC=0.92;>48ms had sensitivity=83%, specificity=89%). Binary logistic regression showed that accuracy was improved when LV dyssynchrony was combined with 2D GLS. HCM was excluded when 2D GLS was preserved (>18%) and there was no LV dyssynchrony (>48ms) and only patients with HCM had reduced longitudinal strain and LV dyssynchrony., Conclusions: LV dyssynchrony combined with GLS can be used to differentiate athletes with moderate LVH from patients with HCM., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)

Published
2017
Full Text
View/download PDF

15. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction.

Author

Gallet R, Ternacle J, Damy T, Guendouz S, Bremont C, Seemann A, Gueret P, Dubois-Rande JL, and Lim P

Subjects
Aged, Cardiotonic Agents administration & dosage, Drug Therapy, Combination, Female, Heart Failure, Systolic physiopathology, Humans, Ivabradine, Male, Middle Aged, Pilot Projects, Prospective Studies, Treatment Outcome, Benzazepines administration & dosage, Dobutamine administration & dosage, Heart Failure, Systolic diagnosis, Heart Failure, Systolic drug therapy, Hemodynamics drug effects, Severity of Illness Index
Abstract

Background: Dobutamine induced tachycardia increases myocardial oxygen consumption and impairs ventricular filling. We hypothesized that Ivabradine may be efficient to control dobutamine induced tachycardia., Methods: We assessed the effects of Ivabradine in addition to dobutamine in stable heart failure (HF) patients (LVEF < 35%, n = 22, test population) and validated its effects in refractory cardiogenic shock patients (n = 9, validation population) with contraindication to cardiac assistance or transplant. In the test population (62 ± 17 years, LVEF = 24 ± 8%), systolic and diastolic function were assessed at rest and under dobutamine [10 γ/min], before and after Ivabradine [5mg per os]. In the validation population (54 ± 11 years, LVEF = 22 ± 7%), Ivabradine [5mg twice a day] was added to the dobutamine infusion., Results: In the test population, Ivabradine decreased heart rate [HR] at rest and during dobutamine echocardiography (-9 ± 8 bpm, P = 0.0004). The decrease in HR was associated with a decrease in cardiac power output and an increase in diastolic duration at rest (+ 74 ± 67 ms, P = 0.0002), and during dobutamine infusion (+ 75 ± 67 ms, P < 0.0001). Change in LVEF during dobutamine was greater after Ivabradine treatment than before (+ 7.2 ± 4.7% vs. + 3.6 ± 4.2%, P = 0.002). In the validation population, Ivabradine decreased HR (-18 ± 11 bpm, P = 0.008) and improved diastolic filling time (+ 67 ± 42 ms, P = 0.012) without decreasing cardiac output. At 24h, Ivabradine improved systolic blood pressure (+ 9 ± 5 mmHg, P = 0.007), daily urine output (+ 0.7 ± 0.5L, P = 0.008), oxygen balance (ΔScv02 = + 13 ± 15%, P = 0.010), and NT-pro BNP (-2270 ± 1912 pg/mL, P = 0.017). Finally, only 2/9 (22%) patients died whereas expected mortality determined from a historical cohort was 78% (P = 0.017)., Conclusion: This pilot study demonstrates the safety and potential benefit of a HR lowering agent in cardiogenic shock., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)

Published
2014
Full Text
View/download PDF

16. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases.

Author

Bernard C, Maucort-Boulch D, Varron L, Charlier C, Sitbon K, Freymond N, Bouhour D, Hot A, Masquelet AC, Valeyre D, Costedoat-Chalumeau N, Etienne M, Gueit I, Jouneau S, Delaval P, Mouthon L, Pouget J, Serratrice J, Brion JP, Vaylet F, Bremont C, Chennebault JM, Jaffuel S, Broussolle C, Lortholary O, and Sève P

Subjects
Adolescent, Adult, Antifungal Agents therapeutic use, CD4 Lymphocyte Count, Cryptococcosis diagnosis, Cryptococcosis drug therapy, Cryptococcosis immunology, Female, Glucocorticoids therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Opportunistic Infections diagnosis, Opportunistic Infections drug therapy, Opportunistic Infections immunology, Prognosis, Retrospective Studies, Sarcoidosis drug therapy, Sarcoidosis immunology, Young Adult, Cryptococcosis complications, Opportunistic Infections complications, Sarcoidosis complications
Abstract

Aim: To describe the main characteristics and the treatment of cryptococcosis in patients with sarcoidosis., Design: Multicenter study including all patients notified at the French National Reference Center for Invasive Mycoses and Antifungals., Methods: Retrospective chart review. Each case was compared with two controls without opportunistic infections., Results: Eighteen cases of cryptococcosis complicating sarcoidosis were analyzed (13 men and 5 women). With 2749 cases of cryptococcosis registered in France during the inclusion period of this study, sarcoidosis accounted for 0.6% of all the cryptococcosis patients and for 2.9% of the cryptococcosis HIV-seronegative patients. Cryptococcosis and sarcoidosis were diagnosed concomitantly in four cases; while sarcoidosis was previously known in 14/18 patients, including 12 patients (67%) treated with steroids. The median rate of CD4 T cells was 145 per mm(3) (range: 55-1300) and not related to steroid treatment. Thirteen patients had cryptococcal meningitis (72%), three osteoarticular (17%) and four disseminated infections (22%). Sixteen patients (89%) presented a complete response to antifungal therapy. After a mean follow-up of 6 years, no death was attributable to cryptococcosis. Extra-thoracic sarcoidosis and steroids were independent risk factors of cryptococcosis in a logistic regression model adjusted with the sex of the patients., Conclusions: Cryptococcosis is a significant opportunistic infection during extra-thoracic sarcoidosis, which occurs in one-third of the cases in patients without any treatment; it is not associated to severe CD4 lymphocytopenia and has a good prognosis.

Published
2013
Full Text
View/download PDF

17. A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes.

Author

Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Piñero A, Wolczynski S, Brailly-Tabard S, Bidet M, Ramos-Arroyo M, Mathieu M, Lienhardt-Roussie A, Morgan G, Turki Z, Bremont C, Lespinasse J, Du Boullay H, Chabbert-Buffet N, Jacquemont S, Reach G, De Talence N, Tonella P, Conrad B, Despert F, Delobel B, Brue T, Bouvattier C, Cabrol S, Pugeat M, Murat A, Bouchard P, Hardelin JP, Dodé C, and Young J

Subjects
Alleles, Body Mass Index, Circadian Rhythm, Cryptorchidism epidemiology, Female, Humans, Hydrocortisone blood, Male, Phenotype, Testis pathology, Testosterone metabolism, Gastrointestinal Hormones genetics, Kallmann Syndrome genetics, Mutation, Neuropeptides genetics, Receptors, G-Protein-Coupled genetics, Receptors, Peptide genetics
Abstract

Context: Both biallelic and monoallelic mutations in PROK2 or PROKR2 have been found in Kallmann syndrome (KS)., Objective: The objective of the study was to compare the phenotypes of KS patients harboring monoallelic and biallelic mutations in these genes., Design and Patients: We studied clinical and endocrine features that reflect the functioning of the pituitary-gonadal axis, and the nonreproductive phenotype, in 55 adult KS patients (42 men and 13 women), of whom 41 had monoallelic mutations and 14 biallelic mutations in PROK2 or PROKR2., Results: Biallelic mutations were associated with more frequent cryptorchidism (70% vs. 34%, P < 0.05) and microphallus (90% vs. 28%, P < 0.001) and lower mean testicular volume (1.2 +/- 0.4 vs. 4.5 +/- 6.0 ml; P < 0.01) in male patients. Likewise, the testosterone level as well as the basal FSH level and peak LH level under GnRH-stimulation were lower in males with biallelic mutations (0.2 +/- 0.1 vs. 0.7 +/- 0.8 ng/ml; P = 0.05, 0.3 +/- 0.1 vs. 1.8 +/- 3.0 IU/liter; P < 0.05, and 0.8 +/- 0.8 vs. 5.2 +/- 5.5 IU/liter; P < 0.05, respectively). Nonreproductive, nonolfactory anomalies were rare in both sexes and were never found in patients with biallelic mutations. The mean body mass index of the patients (23.9 +/- 4.2 kg/m(2) in males and 26.3 +/- 6.6 kg/m(2) in females) did not differ significantly from that of gender-, age-, and treatment-matched KS individuals who did not carry a mutation in PROK2 or PROKR2. Finally, circadian cortisol levels evaluated in five patients, including one with biallelic PROKR2 mutations, were normal in all cases., Conclusion: Male patients carrying biallelic mutations in PROK2 or PROKR2 have a less variable and on average a more severe reproductive phenotype than patients carrying monoallelic mutations in these genes. Nonreproductive, nonolfactory clinical anomalies associated with KS seem to be restricted to patients with monoallelic mutations.

Published
2010
Full Text
View/download PDF

18. [Diabetes insipidus with a hypothalamo-hypophyseal morphologic anomaly during a pregnancy].

Author

Fluteau-Nadler S, Bremont C, Billaud L, Thomopoulos P, and Luton JP

Subjects
Adult, Deamino Arginine Vasopressin therapeutic use, Diabetes Insipidus drug therapy, Diabetes Insipidus pathology, Female, Humans, Hypothalamo-Hypophyseal System pathology, Kidney physiopathology, Magnetic Resonance Imaging, Pregnancy, Pregnancy Complications diagnosis, Pregnancy Complications pathology, Pregnancy Trimester, Third, Renal Agents therapeutic use, Diabetes Insipidus physiopathology, Hypothalamo-Hypophyseal System abnormalities, Pregnancy Complications physiopathology
Abstract

Background: Diabetes insipidus is uncommon in pregnancy. Despite physiological modifications in hydroelectrolytic balance during normal pregnancy, the capacity of the kidney to concentrate urine is preserved, partially due to lower vasopressin secretion., Case Report: A young woman developed diabetes insipidus during the third trimester of normal pregnancy. The disease regressed totally after delivery. However, magnetic resonance imaging revealed a persistent expansive intrasellar image with a high-intensity signal., Discussion: Onset of diabetes insipidus is usually rapidly progressive in pregnancy. Occurring generally during the third trimester in normal pregnancies, diabetes insipidus is generally well tolerated and responds to dDAVP, usually without pituitary abnormally, and regresses after delivery. Two types are distinguished: partially latent diabetes insipidus occurring during pregnancy and due to a central rather than nephrogenic origin; and excessive vasopressinase activity leading to diabetes insipidus usually associated with liver anomalies and high frequency of pre-eclampsia. During normal pregnancy, the size of the anterior pituitary increases and the normal high-intensity signal in the posterior pituitary seen on MRI usually regresses or disappears. In diabetes insipidus, the posterior pituitary hypersignal image generally disappears, reflecting reduced vasopressin storage. Few observations of diabetes insipidus occurring during pregnancy have been reported with morphological explorations. Most have described a "normal" aspect of the pituitary, specifically in the post partum period. In our patient, the weak vasopressin response to the end of water restriction at post partum when the diabetes insipidus symptoms had disappeared would suggest partial central diabetes insipidus revealed by pregnancy. Other pathologies involving this region could also be involved due to the unusual and persistent sellar image, with an expansive process showing a high intensity signal on MRI. An asymptomatic craniopharyngioma cyst was hypothesized and would be more compatible with the observed symptoms.

Published
1998

20. [The place of endocrinology in the management of transsexualism].

Author

Luton JP and Bremont C

Subjects
Female, Humans, Male, Transsexualism diagnosis, Endocrinology, Gonadal Steroid Hormones therapeutic use, Transsexualism drug therapy
Abstract

Transsexualism is not a sexual perversion but rather a gender identity disorder. The patient claim for his personal and public image and condition. The diagnosis problems arise from the lack of clinical, biological or hormonal typical signs. The pathogenesis is unclear but works in progress suggest somatic alterations. These alterations might be pre or perinatal hormonal changes and/or alterations in cerebral structures involved in sexual differentiation. Transsexualism is not a treatable disease using currently available treatments. Only hormonal and surgical treatments with sex reassignment might answer to the patient's request and improve his mental condition. Hormonal treatment might only prescribed after a consensus statement of about the sex reassignment of the patient and under medical follow-up. An early and strict medical follow-up of the patients by a multi specialist medical team is required and have to warrant the etic aspects. This is mostly important for the approval for sex reassignment from the authorities.

Published
1996

21. [Agranulocytosis induced by synthetic antithyroid drugs: efficacy of hematopoietic growth factors].

Author

Genet P, Pulik M, Lionnet F, and Bremont C

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Agranulocytosis chemically induced, Agranulocytosis drug therapy, Antithyroid Agents adverse effects, Granulocyte Colony-Stimulating Factor therapeutic use, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Hormones adverse effects
Abstract

Agranulocytosis is the most serious problem, potentially fatal, that can occur during antithyroid drug therapy. The use of hematopoietic growth factors is an attractive approach to reduce the period of this drug-induced neutropenia. We report two cases of severe antithyroid drug-related agranulocytosis (granulocyte count < 0.1 x 10(9)/L) treated with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). The delay to observe a granulocyte count superior to 1 x 10(9)/L was respectively 1 and 5 days. Our results, with others, clearly show that hematopoietic growth factors are effective in severe antithyroid drug-induced agranulocytosis.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results